Insider trade

Werewolf Therapeutics (HOWL): Director sold ~$17K

Luke Evnin, Director at Werewolf Therapeutics, sold ~$17K of Werewolf Therapeutics shares.

~$17K
Approx. value · 31K sh @ $0.57
2.24M
Holds after · shares reported
Traded
Jan 14, 2026
Filed
Jan 15, 2026

What stands out in this filing

  • The sale was 1.4% of the shares this insider held before it; the filing reports 2,236,055 shares, held indirectly afterwards.
  • 30,616 shares at an average of $0.57 each, as reported on the form.
  • Footnote references a pre-arranged trading plan (Rule 10b5-1).

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 5, 2025InsiderDirector sold ~$16K of HOWL shares in the open market
  2. Dec 8, 2025InsiderDirector sold ~$34K of HOWL shares in the open market
  3. Dec 9, 2025InsiderDirector sold ~$45K of HOWL shares in the open market
  4. Dec 10, 2025InsiderDirector sold ~$39K of HOWL shares in the open market
  5. Dec 11, 2025InsiderDirector sold ~$30K of HOWL shares in the open market
  6. Dec 12, 2025InsiderDirector sold ~$19K of HOWL shares in the open market
  7. Dec 15, 2025InsiderDirector sold ~$25K of HOWL shares in the open market
  8. Dec 16, 2025InsiderDirector sold ~$15K of HOWL shares in the open market
  9. Dec 17, 2025InsiderDirector sold ~$11K of HOWL shares in the open market
  10. Dec 22, 2025InsiderDirector sold ~$41K of HOWL shares in the open market
  11. Dec 23, 2025InsiderDirector sold ~$45K of HOWL shares in the open market
  12. Dec 24, 2025InsiderDirector sold ~$11K of HOWL shares in the open market
  13. Dec 26, 2025InsiderDirector sold ~$22K of HOWL shares in the open market
  14. Dec 29, 2025InsiderDirector sold ~$66K of HOWL shares in the open market
  15. Dec 30, 2025InsiderDirector sold ~$21K of HOWL shares in the open market
  16. Dec 31, 2025InsiderDirector sold ~$15K of HOWL shares in the open market
  17. Jan 2, 2026InsiderDirector sold ~$12K of HOWL shares in the open market
  18. Jan 5, 2026InsiderDirector sold ~$12K of HOWL shares in the open market
  19. Jan 6, 2026InsiderDirector sold ~$26K of HOWL shares in the open market
  20. Jan 7, 2026InsiderDirector sold ~$7.6K of HOWL shares in the open market
  21. Jan 8, 2026InsiderDirector sold ~$4.9K of HOWL shares in the open market
  22. Jan 9, 2026InsiderDirector sold ~$15K of HOWL shares in the open market
  23. Jan 12, 2026InsiderDirector sold ~$34K of HOWL shares in the open market
  24. Jan 13, 2026InsiderDirector sold ~$24K of HOWL shares in the open market
  25. Jan 14, 2026 · this disclosureInsiderDirector sold ~$17K of HOWL shares in the open market

What came next

  1. Jan 15, 2026InsiderDirector sold ~$21K of HOWL shares in the open market
  2. Jan 16, 2026InsiderDirector sold ~$21K of HOWL shares in the open market
  3. Feb 4, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On February 4, 2026, Werewolf Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum bid price required to maintain…”
  4. Feb 9, 2026Company filing · Form 8-K · Restructuring, Executive changeAnnounced job cuts, closures or a restructuring, and changed a top executive or board member (and 1 more item)“Departure of Certain Officers As part of the Reduction, on February 9, 2026, the Company and each of Timothy W. Trost, Chief Financial Officer of the Company, and Dr. Randi Isaacs, M.D., Chief Medical Officer of the Company, agreed that Mr. Trost and Dr. Isaacs would resign as Chief Financial Officer and Chief Medical Officer, as applicable, effective February 13, 2026.”
  5. Mar 27, 2026Company filing · Form 8-K · ResultsReported its results
  6. Apr 27, 2026InsiderDirector sold ~$46K of HOWL shares in the open market
  7. Apr 28, 2026InsiderDirector sold ~$70K of HOWL shares in the open market
  8. Apr 29, 2026InsiderDirector sold ~$39K of HOWL shares in the open market
  9. Apr 30, 2026InsiderDirector sold ~$121K of HOWL shares in the open market
  10. May 1, 2026InsiderDirector sold ~$43K of HOWL shares in the open market
  11. May 4, 2026InsiderDirector sold ~$35K of HOWL shares in the open market
  12. May 6, 2026InsiderDirector sold ~$9.7K of HOWL shares in the open market
  13. May 7, 2026Company filing · Form 8-K · ResultsReported its results
  14. May 7, 2026InsiderDirector sold ~$50K of HOWL shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Werewolf Therapeutics

For Werewolf Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HOWL page.

Other recent filings by Luke Evnin, Director

The full history of Luke Evnin, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Werewolf Therapeutics (HOWL) insider traded, and how much?

Luke Evnin, Director at Werewolf Therapeutics, sold ~$17K of Werewolf Therapeutics shares. 31K shares at $0.57.

When did it happen, and when was it made public?

Traded: Jan 14, 2026. Filed: Jan 15, 2026. That is 1 day between the two dates.

What stands out in this filing?

The sale was 1.4% of the shares this insider held before it; the filing reports 2,236,055 shares, held indirectly afterwards. 30,616 shares at an average of $0.57 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Werewolf Therapeutics recently?

For Werewolf Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the HOWL page.

Does this mean HOWL stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Werewolf Therapeutics

Everything OQRO holds on this company is on its HOWL page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data